The DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index; 15 of the 67 sources its claims cite were checked for support.
Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation
Open accessAbstract
One of the benefits of Digital PCR (dPCR) is the potential for unparalleled precision enabling smaller fold change measurements. An example of an assessment that could benefit from such improved precision is the measurement of tumour-associated copy number variation (CNV) in the cell free DNA (cfDNA) fraction of patient blood plasma. To investigate the potential precision of dPCR and compare it with the established technique of quantitative PCR (qPCR), we used breast cancer cell lines to investigate HER2 gene amplification and modelled a range of different CNVs. We showed that, with equal experimental replication, dPCR could measure a smaller CNV than qPCR. As dPCR precision is directly dependent upon both the number of replicate measurements and the template concentration, we also developed a method to assist the design of dPCR experiments for measuring CNV. Using an existing model (based on Poisson and binomial distributions) to derive an expression for the variance inherent in dPCR, we produced a power calculation to define the experimental size required to reliably detect a given fold change at a given template concentration. This work will facilitate any future translation of dPCR to key diagnostic applications, such as cancer diagnostics and analysis of cfDNA.
Overview
CoChat Summary
TL;DR
This study directly compares microfluidic digital PCR (dPCR) with conventional quantitative PCR (qPCR) for measuring HER2 copy number variation using breast cancer cell line DNA and spiked DNA models. It reports that dPCR can detect smaller CNVs than qPCR at equal replication and provides a Poisson/binomial variance model with power calculations to design dPCR experiments based on template concentration.
Key findings
- dPCR and qPCR gave similar HER2:RNase P ratios for normal female gDNA (1.03 vs 1.00; P = 0.39), MCF-7 (0.44 by both; P = 0.71), and T-47D (2.00 vs 1.96; P = 0.52), but SK-BR-3 was significantly lower by dPCR (7.15) than qPCR (9.43; P = 0.00005).
- In an in vitro gene-amplification model at low copy number (2.1 ng/μl; λr ≈ 0.2), dPCR detected a ratio of ≥1.17 with eight panels (P < 0.0003), whereas qPCR detected ratios of ≥1.27 with eight wells (P < 0.0005); a 1.12 ratio was not significantly different from normal female gDNA by dPCR with eight panels, and ratios ≤1.22 were not significantly different by qPCR.
- Power calculations predicted that with 95% power and λr = 0.2, a 1.2-fold change was detectable with five 770-chamber panels per assay, ratios of 1.1 and below required >15 panels, and the smallest CNV measurable with eight panels was approximately 1.15.
- For qPCR, power curves indicated ratios greater than 1.25 could be measured with 95% power and eight replicate wells, while an excess of 20 qPCR wells would be needed to measure ratios of 1.17 or fewer.
Methods
- Genomic DNA from three breast cancer cell lines with different HER2 status (SK-BR-3, T-47D, MCF-7) and pooled normal female gDNA was analyzed with HER2 and RNase P assays by qPCR and microfluidic dPCR on 48.770 arrays.
- An in vitro CNV model was created by spiking T-47D gDNA into normal female gDNA to generate theoretical HER2:RNase P ratios between 1.00 and 2.00 at low copy number.
- dPCR quantification used Poisson estimation of molecules per chamber (λ = −ln(1 − H/C)); qPCR used standard curves. Statistical comparisons used ANOVA and two-tailed Student’s t-tests, and power calculations were performed in R based on a derived variance model for the log ratio.
Limitations
- Stated: the proof-of-principle experiments used high-quality DNA template to model cfDNA; translation will require consideration of template integrity, PCR-assay efficiency, and matrix effects.
- Stated: dPCR may not accurately quantify concatameric HER2 amplifications such as those in SK-BR-3, and pre-amplification to separate linked copies requires careful validation because of potential bias.
- Evident from the text: the findings are tied to one microfluidic dPCR platform (Fluidigm 48.770), specific HER2/RNase P assays, and a one-tailed power model focused on HER2 amplification, so generalizability to other platforms, assays, or deletion/two-tailed CNV settings is not established here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
13 Valid · 1 Not valid · 16 Not checked · 62 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Analysis of the SK-BR-3 gDNA identified high levels of HER2 amplification that corresponds with the published copy number range (14–24 copies per diploid genome) (41,43–45,47).”
§ Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [41] Konigshoff, 2003, HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue, Clin. Chem. source
- Not checked — no full text of the sourcecites [43] Sestini, 1995, Gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2, and N-myc measured by quantitative PCR with a multiple competitor template, Clin. Chem. source
- Not checked — no full text of the sourcecites [44] Lyon, 2001, Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis, Clin. Chem. source
- Partly supportedcites [45] Millson, 2003, Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification, J. Mol. Diagn. sourceExperimental — accuracy not yet measured
The Results (p. 4) report high HER2/neu amplification in SKBR3, with a gene dose of 10 relative to the single-copy MRC-5 control; the competitive PCR results (p. 4) give a dose of 11. Our copy does not state the claimed published range of 14–24 copies per diploid genome or explicitly equate its measurements with that range. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [47] Hynes, 1989, Overexpression of the c-erbB-2 protein in human breast tumor cell lines, J. Cell Biochem. source
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“it is also essential that some estimation of efficiency is made (25).”
§ Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation > DISCUSSION
What the sources say
- Supportedcites [25] Bustin, 2009, The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments, Clin. Chem. source
Section 7.4 lists PCR efficiency as a required assay-performance measurement. Section 7.4.1 says amplification efficiency must be established using calibration curves and explains that differences in efficiency can make comparisons of relative concentrations inaccurate. This supports the need to estimate efficiency when measuring fold changes. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“T-47D gDNA gave a HER2:RNase P ratio of < 2 (3–4 copies per diploid genome) (43–46).”
§ Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [43] Sestini, 1995, Gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2, and N-myc measured by quantitative PCR with a multiple competitor template, Clin. Chem. source
- Not checked — no full text of the sourcecites [44] Lyon, 2001, Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis, Clin. Chem. source
- Partly supportedcites [45] Millson, 2003, Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification, J. Mol. Diagn. sourceExperimental — accuracy not yet measured
Sample Preparation (p. 2) and Results (p. 4) describe T47D as having approximately four HER2/neu copies, supporting the copy-number portion of the claim. The paper uses β-globin, not RNase P, as its reference gene; Results (p. 4) reports a T47D gene dose of 2, and the β-globin section (p. 4) reports 2.2 by the other method. It therefore does not support a HER2:RNase P ratio below 2. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [46] Dati, 1990, Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells, Oncogene
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This is a crucial consideration when considering cfDNA as a template as its concentration can range considerably; from 2 to 30 ng/ml plasma in healthy individuals to 180–600 ng/ml plasma both during pregnancy and in cancer patients (13,16,18,22–24).”
§ Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [13] Leon, 1977, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res.
- Not checked — no full text of the sourcecites [16] Levenson, 2007, Biomarkers for early detection of breast cancer: what, when, and where? Biochim, Biophys. Acta source
- Not checked — no full text of the sourcecites [18] Jung, 2010, Cell-free DNA in the blood as a solid tumor biomarker–a critical appraisal of the literature, Clin. Chim. Acta source
- Not checked — no full text of the sourcecites [22] Fournie, 1986, Recovery of nanogram quantities of DNA from plasma and quantitative measurement using labeling by nick translation, Anal. Biochem. source
- Not checked — no full text of the sourcecites [23] Giacona, 1998, Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls, Pancreas source
- Partly supportedcites [24] Diehl, 2005, Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc. Natl Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Results (page unavailable) report more circulating APC gene fragments in advanced colorectal cancer patients than in donors without tumors, supporting the general point that plasma DNA levels vary. The paper gives fragment counts per ml, not the claimed 2–30 or 180–600 ng/ml concentration ranges, and it does not report cfDNA concentrations during pregnancy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, a CNV ratio of 1.17 was significantly detected using eight panels”
§ Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 92 claims and to verify the 2 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 31
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since we applied the same assay and samples for both platforms, these differences most likely arise from general technical differences, causing a certain degree of measurement uncertainty that can influence the precision of estimates especially at the lower range of copy number concentrations42,53,54.”
From Comparing the precision of two digital PCR applications for copy number comparisons in protists (2025) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Shlien, 2010, Copy number variations and cancer susceptibility, Curr. Opin. Oncol., 22, 55, 10.1097/CCO.0b013e328333dca4”
Cited work 10.1097/cco.0b013e328333dca4 · retracted 2016-09-01 · notice 10.1097/01.cco.0000491182.00738.ba · this paper published 2012-02-28
Citations
Cites
1 retracted
Copy number variations and cancer susceptibility
Shlien, A., & Malkin, D. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328333dca4 · Cited by 77
RetractedA new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303 · cited 7×
“Real-time quantitative PCR was performed in accordance with the MIQE guidelines (Supplementary Table S1 and Supplementary Figure S1) (25).”
BackgroundMethodInfluentialSelf-citationSlamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number
Hindson, B. J., Ness, K. D., Masquelier, D. A., Belgrader, P., Heredia, N. J., Makarewicz, A. J., Bright, I. J., Lucero, M. Y., Hiddessen, A. L., Legler, T. C., et al. (2011) · Analytical Chemistry · doi:10.1021/ac202028g · Cited by 2,792
(1977) · PubMed · Cited by 1,801
Copy number variation in human health, disease, and evolution
Zhang, F., Gu, W., Hurles, M. E., & Lupski, J. R. (2009) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164217 · Cited by 1,207
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Detection and quantification of mutations in the plasma of patients with colorectal tumors
Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507904102 · Cited by 1,188
Cited by
Huggett, J. F., Foy, C. A., Benes, V., Emslie, K., Garson, J. A., Haynes, R., Hellemans, J., Kubista, M., Mueller, R. D., Nolan, T., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206375 · Cited by 859
Self-citationQuan, P.-L., Sauzade, M., & Brouzes, E. (2018) · Sensors · doi:10.3390/s18041271 · Cited by 664
“In agreement with statistical considerations, dPCR precision depends on both the number of replicates and the template concentration [33].”
BackgroundInfluentialThe dMIQE Group, Whale, A. S., De Spiegelaere, W., Trypsteen, W., Nour, A. A., Bae, Y.-K., Benes, V., Burke, D., Cleveland, M., Corbisier, P., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa125 · Cited by 516
“Restriction digestion to small linear DNA fragments may equalize template differences (36, 49, 64), and prevent underestimation of linked target molecules (18).”
BackgroundSelf-citationBaker, M. (2012) · Nature Methods · doi:10.1038/nmeth.2027 · Cited by 524
Highly Precise Measurement of HIV DNA by Droplet Digital PCR
Strain, M. C., Lada, S. M., Luong, T., Rought, S. E., Gianella, S., Terry, V. H., Spina, C. A., Woelk, C. H., & Richman, D. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055943 · Cited by 504
“Digital PCR (dPCR) [2], in which the amplification reaction is divided into thousands of microscopic reaction volumes, is a rapidly growing alternative that is potentially more accurate [3,4,5] and more precise [6,7].”
Background
Metadata
- Authors
- Whale, A. S., Huggett, J. F., Cowen, S., Speirs, V., Shaw, J., Ellison, S., Foy, C. A., & Scott, D. J.
- Affiliations
- University of Leeds (GB)
- Corresponding author
- Huggett, Jim F.
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02-28
- Volume
- 40
- Issue
- 11
- Pages
- e82-e82
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC3367212
- OpenAlex
- W2096206246
- Cited by
- 453
- References
- 53
- Citations by year
- 2026: 33 · 2025: 32 · 2024: 20 · 2023: 36 · 2022: 29 · 2021: 36 · 2020: 33 · 2019: 34 · 2018: 24 · 2017: 32 · 2016: 48 · 2015: 31 · 2014: 30 · 2013: 27 · 2012: 6
- FWCI
- 12.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Government of the United Kingdom
- Cancer Research UK (13462)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Molecular Biology Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Keywords
- digital PCR, copy number variation, real-time PCR, measurement precision, cell-free DNA, breast cancer cell lines, HER2 amplification, power analysis, template concentration, cancer diagnosis
- MeSH terms
- DNA, Neoplasm, Female, Gene Amplification, Humans, Polymerase Chain Reaction, Gene Dosage, Genes, erbB-2, Cell Line, Tumor, Microfluidic Analytical Techniques, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. https://app.cochat.ai/papers/10.1093/nar/gks203
- The paper
- Whale, A. S., Huggett, J. F., Cowen, S., Speirs, V., Shaw, J., Ellison, S., Foy, C. A., & Scott, D. J. (2012). Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Research. https://doi.org/10.1093/nar/gks203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.